Humulin S (Soluble)

Humulin S (Soluble) is an injectable solution that contains insulin human as its active ingredient. It is supplied in the European market as a sterile liquid for intravenous or subcutaneous administration. The product provides a short‑acting form of insulin that mimics the body’s natural hormone, helping to regulate blood glucose levels in patients with diabetes. Humulin S is stored in a refrigerator and must be used according to healthcare guidance.

Humulin S (Soluble) is indicated for the management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus - Type 2 diabetes mellitus - Basal‑bolus insulin regimens combined with longer‑acting insulins - Correction of post‑prandial hyperglycemia - Intravenous insulin infusion in hospital settings - Use during pregnancy when insulin therapy is required, following specialist guidance

Adverse reactions to Humulin S may occur; they are categorized by frequency and severity.

Common: - Hypoglycemia (low blood glucose) - Injection‑site pain or bruising - Lipodystrophy at the injection site - Weight gain - Mild skin rash or itching

Serious: - Severe hypoglycemia with loss of consciousness or seizures - Anaphylactic or severe allergic reaction - Hypokalemia (low potassium levels) - Pulmonary edema or fluid retention - Bronchospasm associated with hypersensitivity

Before using Humulin S, consider the following safety measures.

- Regularly monitor blood glucose and adjust dose as needed - Adjust dosing during illness, pregnancy, or renal/hepatic impairment - Avoid use in patients with known hypersensitivity to human insulin - Use cautiously in individuals with cardiovascular disease - Educate patients on recognizing and treating hypoglycemia - Store the product in a refrigerator and protect from light - Do not mix with other insulins unless compatibility is confirmed

Humulin S can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Simultaneous use of other rapid‑acting insulins without dose adjustment - Unsupervised combination with GLP‑1 receptor agonists that may increase hypoglycemia risk

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms - Thiazide diuretics, which may raise blood glucose levels - Corticosteroids, which can increase insulin requirements - ACE inhibitors or ARBs, which may potentiate hypoglycemia - Alcohol consumption, which can potentiate insulin’s glucose‑lowering effect